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ABSTRACT
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous pollutants with toxic effects and adverse health impacts on 
general population. Several methods of extraction had been applied to extract PAHs from human blood samples such 
as solid phase extraction (SPE). The SPE represents one of the most common techniques for extraction and clean-up 
procedures as it needs low quantity of solvents with less manual efforts. Similarly, various analytical instruments like 
gas chromatography coupled to mass spectrometry (GC-MS) was used to measure the PAHs levels. Gas chromatog-
raphy is a simple, fast, and very efficient method for solvents and small organic molecules. This review provides an 
overview of the measured concentrations of PAHs in human blood samples through the application of SPE and GC-
MS during the last ten years. While these studies used various solvents, their application of SPE method and GC-MS 
revealed rewarding results about the determination of PAHs levels in the human samples.
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INTRODUCTION
Polycyclic aromatic hydrocarbons (PAHs) represent 
a group of common pollutants around the globe 
produced concurrently with incomplete combustion of 
organic compounds and delivered to the environment 
through vehicles emissions, industrial sources, cigarette 
smoke, and waste incineration (1). The United States 
Environmental Protection Agency (USEPA) specified 
16 PAHs as priority compounds due to their toxicity 
on human health. These 16 PAHs include naphthalene 
(Nap), acenaphthene (Ace), acenaphthylene (A), 
fluorene (F), anthracene (Ant), phenanthrene (Phe), 
pyrene (Pyr), fluoranthene (Flu), benz(a)anthracene 
(BaA), benzo(b+k)fluoranthene (B(b+k)Flu), chrysene 
(Chr), benzo(a)pyrene (Bap), dibenzo(a,h)anthracene 
(DA), benzo(g,h,i)perylene (BP), and indeno(1,2,3-cd)
pyrene (IcdP) (2). Based on the number of benzene 
rings in their structures, PAHs can be classified into low 
molecular weight (LMW-PAHs) (2-3 rings), medium 
molecular weight (MMW-PAHs) (4 rings), and high 
molecular weight (HMW-PAHs) (5-6 rings) (3). While 
LMW-PAHs are only toxic, the HMW-PAHs are both 
toxic and carcinogenic (2).  (2). 
Human are exposed to PAHs in both occupational 
and non-occupational settings through various routes 
of exposure such as inhalation, ingestion, and dermal 
contact. Moreover, some exposures could affect the 
total absorbed dose by having more than one route 
simultaneously (such as inhalation and dermal exposures 
from contaminated air) (4). Interestingly, the emissions 
of complex mixtures of PAHs into the atmosphere depict 
a possible health risk to the human being. Furthermore, 
the short-term impacts of PAHs on an individual count 
massively on the exposure duration, concentrations, 
toxicity, and route of exposure to PAHs (4). These 
acute health effects include impaired lung function in 
asthmatics and thrombotic effects in people affected by 
coronary heart disease (5). However, the chronic health 
effects of PAHs include its carcinogenic possibility, 
specifically lung malignancy in addition to skin tumour 
and bladder cancer (6).  
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Recognition of these health risks is very crucial and may 
be achievable when enough data about the amount and 
duration of PAHs exposure are available. Even though 
ambient air concentrations of PAHs may be applied to 
assess these exposures, body biomarkers such as whole 
blood, serum or urine samples give more precise data 
about the amount of exposure as well as retention of 
these compounds  (7)Furthermore, most PAHs can be 
detected in blood samples while their metabolites are 
found in urine samples (8). There are various extraction 
methods of PAHs from biological samples such as solid 
phase extraction (SPE) and liquid-liquid extraction as 
well as their corresponding analytical method e.g. gas 
chromatography coupled to mass spectrometry (GC-MS) 
and high- performance liquid chromatography (HPLC) 
(8, 9). 
SPE offers many benefits and advantages over other 
traditional sample preparation techniques (such as 
liquid-liquid extraction) including high recoveries 
and excellent concentrations of the analytes, highly 
purified extracts, ease of automation, compatibility 
with instrumental analysis, and reduction in organic 
solvent consumption  (10).  Selection of solvent for SPE 
is based on the type of SPE column such as reverse-
phase or normal-phase type. Furthermore, activation 
solvent should be able to wet the SPE column sorbent 
well and compatible with the solvent for equilibration. 
Also, solvents for equilibration should be compatible 
with the activation solvent, wet the sorbent well, and 
of low elution power. Solvents for collection should be 
compatible with previously used elution solvent, and 
can remove the targeted compounds with small volume 
and easy to evaporate.
This review is aimed to briefly assess the concentrations 
of PAHs in blood samples and their influences on the 
human health, and to discuss the SPE method used in 
their extraction as well the GC-MS used in their analysis 
from the year 2009 to 2019. In addition, this study 
compares the total sera concentrations of PAHs, the 
highest and lowest PAH compounds, and the HMW-
PAHs and LWM-PAHs concentrations among studies 
done over the world in the last ten years. These serum 
samples may highly be associated with PAHs exposure 
in addition to their retention, therefore giving a clear 
picture about PAHs exposure.
METHODOLOGY
This article reviewed the concentrations of PAHs in 
blood samples and their influences on the human health 
from the year 2009 to 2019 (3, 10-14). In addition, the 
SPE methods used in their extraction as well as the GC-
MS used in their analysis were discussed. These data 
were compiled through literature databases such as 
Google Scholar and Scopus. Various concentrations 
of blood serum PAHs were reviewed in tandem with 
their extraction and analysis methods. Besides that, the 
health effects of these PAHs were briefly discussed in 
this review. 
 
RESULTS AND DISCUSSION
Extraction and analysis of PAHs in human blood samples
Six studies were reviewed according to the using of SPE 
and GC-MS methods in the extraction and analysis of 
PAHs compounds in blood serum and whole blood 
samples (Table I). Although all selected studies were 
using SPE method for extraction and clean-up processes, 
each study applied different solvents to extract the PAHs 
compounds. In this section, details concerned with 
solvents and the type of SPE cartridge were reviewed. 
Also, the limit of detection (LOD) which is defined as the 
smallest concentration of analyte in the test sample that 
can be reliably distinguished from zero, and recoveries 
of PAHs in these selected studies were discussed.. 
Recovery rate represents the accuracy of the extraction 
and is determined by the percentage of analyte that was 
measured after being processed through the SPE device.
Tsang et al. (2011) (11) used dichloromethane (DCM), 
methanol, milli-q water, and n-hexane during the 
extraction and clean-up procedures. The clean-up 
procedure included SPE (High Capacity C18 end-
capped, Alltech Associates Inc.) and micro-florisil 
column. The limit of detection (LOD) was not mentioned 
in the study while the recovery rate of PAHs was ranged 
between (71-126%).  
Moreover, Wang et al. (2015) (12) and Yu et al. (2011) (14) 
were using similar solvents such as acetonitrile, sodium 
sulfate, n-hexane, and a chromatography column filled 
with the silica gel during the SPE and clean-up methods 
of PAHs. However, different matrices were selected in 
their studies including blood serum and whole blood, 
respectively (12, 14). Also, the detection limits in both 
studies were applied different units of measure. While 
the LOD was 0.05-0.10 ng/mL in the first study, the LOD 
in the second study was based on fresh weight (fw) and 
was 0.012-0.025 ng/g fw. Despite that, the recovery rates 
in both studies were approximately close with values of 
67.4-106% and 73.3-121%, respectively (12, 14).
Methanol, M phosphate buffer, acetonitrile, n-butyl 
chloride, and ethyl acetate were utilized as solvents 
during the SPE extraction and clean-up processes by 
Ramesh et al. (2015) (3). However, the type of SPE 
columns, which used in this study, was not specified. 
Besides that, the PAHs LOD as well as their recoveries 
were not reported, despite mentioning the LOD 20-
5000 ng/mL in relation to benzoylecgonine (the primary 
metabolite of cocaine). 
In another study by Guo et al. (2012) (10), who included 
some solvents such as n-hexane, water ethanol, sodium 
hydroxide, milli-q ultrapure water, and DCM for the SPE 
extraction and clean-up procedures. Unlike the  study 
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Table I: Type of matrix, number of PAHs analysed, reported concentration of PAHs, method of extraction and its reagents, sample clean-up meth-
od, type of analytical instrument and sensitivity of each reviewed studies
Matrix Sample 
size
PAHs Reported concentra-
tion of PAHs 
Sample extraction & 
Reagents
Sample clean-up Analytical 
instrument
LOD & Recovery Reference
Blood serum 1-2 mL 16 PAHs - 1461 ng/g fat 
(maternal serum)
- 1158  ng/g fat  
(cord  blood serum)
SPE
- DCM 
- Methanol 
- Milli-Q water
- n-hexane
SPE column
- High Capacity C18 
- Micro-florisil 
column
GC-MS - NA
- 71-126%
(10)
Blood serum 2 mL 27  
PAHs
- 5839  ng/g fat
(cases)
- 2668  ng/g fat
(controls)
SPE
- Acetonitrile
- Sodium sulfate 
- n-hexane
- 200-300 silica gel 
mesh
GC-MS - 0.05-0.10 ng/mL
- 67.4-106%
(11)
Blood serum 2 mL 16 PAHs - 0.3-19 ng/mL SPE
- Methanol 
- M phosphate buffer
- n-butyl chloride
- Ethyl acetate
SPE column
- Sigma SPE col-
umns
GC-MS - 20-5000 ng/mL
- NA
(9)
Blood serum 2 mL 16 PAHs - 206  ng/g fat  SPE
- Formic acid 
- Ethanol 
- n-hexane
- DCM 
- Column filled with 
pre-activated silica 
gel and sodium 
sulfate
GC-MS - 0.013-0.912 ng/mL
- 70.2-103.4%
(12)
Umbilical 
cord blood 
5 mL 15 PAHs - 2560  ng/g fat  SPE
- Acetonitrile
- Sodium sulfate 
- n-hexane 
- 200-300 silica gel 
mesh 
GC-MS - 0.012-0.025 ng/g 
fresh weight
- 71%
(13)
Umbilical 
cord blood
NA 7 PAHs - 108.05 ng/mL
(cases)
- 79.36 ng/mL
(controls)
SPE
- n-hexane
- Water ethanol
- Sodium hydroxide
- Mill-Q ultrapure
- DCM
SPE column
- Supelco RP-18  
cartridges
GC-MS - 0.03-0.09 ng/mL
- 78.2-105.6 %
(8)
N.A. stands for data not available from the study
reported by Ramesh et al. (2015) (3), the type of SPE 
column that used for cleaning up the sample was stated 
in this study and it was RP-18 cartridge (Supelco) (10). 
Moreover, this study showed better LOD of PAHs 0.03-
0.09 ng/mL in addition to recovery rates with values of 
78.2-105.6% (10).   
Furthermore, formic acid, ethanol, n-hexane, and DCM 
were used as solvents by Yin et al. (2017) (13). A column 
chromatography packed with pre-activated silica gel 
and sodium sulfate was applied for the clean-up process. 
The LOD in this study was 0.013-0.912 ng/mL, which 
was the best among all selected studies (3, 10-12, 14). 
Likewise, the recovery range of PAHs in this study was 
also the best compared to other studies that ranged from 
83.1% to 122% (13).
Concentration of PAHs in human blood samples and 
their influences on health
A total of six studies from the past ten years were 
reviewed in terms of concentration of PAHs in human 
blood samples (Table I). While four of these studies used 
blood serum (2 mL) for the detection of PAHs, only two 
studies used whole blood for measuring concentration 
of PAHs (Table I). 
Approximately (30-50 mL) of blood was withdrawn from 
thirty participants, and serum was obtained subsequently 
via blood centrifuging at 3500 rpm (for 5 min) in a 
study done in Hong Kong  (11).  Also, lipid contents 
in blood serum were determined gravimetrically and 
the PAHs analysis was carried out using GC-MS. The 
total concentrations of sixteen PAHs found in maternal 
and cord sera of the subjects were 1461 and 1158 ng 
g−1 fat, respectively. This difference between maternal 
and cord sera PAHs could be belong to the difference in 
lipid compositions of both sera (maternal serum 0.53% 
vs cord serum 0.45%).  The manifestation of cord serum 
PAHs represents antenatal exposure of foetus to those 
harmful compounds. While Nap had the highest levels 
in both types of serum (maternal serum: 331 ng g-1 fat, 
cord serum: 348 ng g-1 fat), B(b+k)Flu had the lowest 
levels in both types of serum (maternal serum: 16 ng g-1 
fat, cord serum: 20 ng g-1 fat). LMW-PAHs were found 
in 100% of all human serum samples. However, HMW-
PAHs compounds were not found in the serum samples 
except B(b+k)Flu (11). 
In another study carried out by Wang et al. (2015) (12), the 
relationship between maternal serum concentrations of 
PAHs and neural tube defect (NTD) risk in offspring was 
investigated using a case-control study design. The study 
was conducted in Northern China and 117 women who 
delivered NTD-affected infants (cases) and 121 women 
who had healthy pregnancies (controls) were included. 
Blood samples were collected from all participants during 
delivery or termination of NTD-affected pregnancies, 
and maternal serum was gathered within one hour of 
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collection. Triglycerides and cholesterol levels were 
measured using the oxidative method, and the GC-MS 
was used for the analysis of PAHs. The sum of serum 
LMW-PAHs, HMW-PAHs, and all PAHs in cases were 
double the values determined in the controls (4712 vs 
2068 ng g-1 fat, 1164 vs 557 ng g-1 fat, 5839 vs 2668 ng 
g−1 fat), respectively. Concurrently, the sum of HMW-
PAHs was reported to have greater odd ratio (OR) values 
in comparison to the sum of LMW-PAHs. This could be 
explained by the fact that five out of the six detected 
HMW-PAHs are carcinogenic, and their greater potency 
could lead to extra oxidative stress damage than that 
shown by the LMW-PAHs, thereby results in a greater 
risk for NTDs in the exposed pregnancies. PHE had the 
highest serum levels in both cases and controls (1820 
vs 796 ng g-1 fat), which possesses structure of three 
rings in addition to represent a very common element 
in traffic emissions. Also, PHE has shown greater serum 
levels in traffic policemen in, China (15). However, BkF 
had the lowest serum levels in both cases and controls 
(32.2 vs 11.3 ng g-1 fat). 
Interestingly, a study was done in US to report the 
concentrations of PAHs in blood sera samples of 650 
autopsied human who died due to different causes (3). 
SPE and clean-up were used to extract PAHs from two 
millilitre of blood serum. PAHs analysis was done using 
GC-MS, however the lipid contents were not assessed. 
The PAHs concentrations reported in this study were 
(0.3-19 ng/mL), and were within the range measured in 
other studies [(0.37–260 ng/mL) (9); (0.15–5.45 ng/mL) 
(16); (3.0–231 pg/mL) (17)] for normal people. Despite 
that, some concentrations measured in this study showed 
great values, which resulted from mixed exposures 
as well as the environmentally poor quality of study 
area. Moreover, several autopsied samples belonged 
to individuals with drug abuse, who mostly could have 
been subjected to tobacco as well as narcotics smoke. 
However, this study did not mention the highest and 
lowest PAH compounds. 
The concentrations of 16 PAHs compounds and their 
possible impact on levels of reproductive hormone in 
the umbilical cord (UC) serum of 98 mother-neonate 
pairs was assessed by Yin et al. (2017) (13). Briefly, two 
millilitre of blood serum was required for the extraction 
and clean-up processes that followed the SPE methods 
in order to evaluate the exposure to PAHs in the sera 
samples of mothers and their neonates. Total fat in the 
serum was measured and was applied to normalize the 
concentration of every compound. Besides that, the 
reproductive hormones such as testosterone, estradiol, 
follicle-stimulating hormone (FSH), luteotropic 
hormone (LH) and Anti-Mullerian hormones (AMH), 
were measured using enzyme-linked immunosorbent 
assay (ELISA) kits. The mean value of total serum 
concentrations of the sixteen PAHs was 206 ng g-1 fat, 
and it showed lesser value than those reported among 
the previous studies (3, 11, 12). The reason behind that 
may be the rural area, where the samples were taken, has 
lesser industrialization in comparison to the developed 
cities as the body burden of PAHs may be related to that. 
While pyrene represented the highest PAH compound 
with a mean value of 98 ng g-1 fat, acenaphthylene 
showed the lowest PAH compound with a mean value 
of 0.297 ng g-1 fat. Additionally, LMW-PAH pollutants 
were the majority (68%) in UC serum in comparison to 
only (32%) represented by HMW-PAHs pollutants.  
Albeit the preceding four studies were done on blood 
serum, the next two studies were carried out using 
whole blood. Firstly,  Yu et al. (2011) (14) investigated 
the PAHs concentrations in 40 non-smoking mothers 
as 30-100 mL UC blood were collected from each 
participant at the time of delivery in Beijing, China. 
The mean value of total concentration of fifteen PAHs 
in the UC blood sample was 2560 ng/g fat. While the 
LMW-PAHs were the predominant PAHs, HMW-PAHs 
showed relatively low levels.  Furthermore, PHE was the 
highest PAH compound with a value of 763 ng/g fat. 
Nevertheless, IcdP showed the lowest value 4.73 ng/g 
fat among all PAHs compounds. 
Secondly, Guo et al. (2012) (10) had conducted 
a study in order to assess the correlation between 
serious environmental pollution of PAHs emitted from 
unregulated electronic-waste recycling and probable 
neonatal health risk in Guiyu, China. One hundred three 
UC blood samples were gathered from exposed area, 
and eighty samples from the control area to evaluate 
the body burden of seven carcinogenic PAHs. The 
PAHs were extracted and cleaned up using solid phase 
methods, then determined by GC-MS. The median value 
of all 7 PAHs concentration was greater in Guiyu 108.05 
ng/mL in comparison to samples from control area 
79.36 ng/mL. Living in Guiyu and prolonged process 
of food cooking at the time of pregnancy were strongly 
correlated with total levels of PAHs. BaA, Chr, and BaP 
were contributing to short neonatal height and reduced 
gestational age. In addition, these congeners showed 
significantly higher levels in infants with unfavourable 
birth outcomes in comparison to infants with healthy 
outcomes. Therefore, mothers who exposed to PAHs 
could suffer potential accumulation of toxic PAHs, and 
thereby could cause adverse effects on the health of 
their neonatal.
CONCLUSION
Currently, studies tend to use human blood samples to 
assess the PAHs exposure as non-metabolized PAHs 
represent excellent biomarker to reflect body burden. 
Although different solvents were used in these studies, 
SPE method showed highly promising sensitivity in 
extraction of PAHs compounds. Moreover, GC–MS 
is still needed to determine the level of PAHs in the 
biological samples, and its use to analyse PAHs has been 
prevalent with robust results in many studies. Further 
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studies are demanded to identify the best solvents 
and SPE columns used for the extraction and clean-up 
procedures of PAHs. Also, these futuristic studies will 
provide extra information on the dose and retention of 
PAHs in biological samples as well as the toxic impacts 
of PAHs on the human health.
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